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A COMPARISON OF NEFAZODONE, THE COGNITIVE BEHAVIORAL-ANALYSIS
SYSTEM OF PSYCHOTHERAPY, AND THEIR COMBINATION
FOR THE TREATMENT OF CHRONIC DEPRESSION
MARTIN B. KELLER, M.D., JAMES P. MCCULLOUGH, PH.D., DANIEL N. KLEIN, PH.D., BRUCE ARNOW, PH.D.,
DAVID L. DUNNER, M.D., ALAN J. GELENBERG, M.D., JOHN C. MARKOWITZ, M.D., CHARLES B. NEMEROFF, M.D., PH.D.,
JAMES M. RUSSELL, M.D., MICHAEL E. THASE, M.D., MADHUKAR H. TRIVEDI, M.D., AND JOHN ZAJECKA, M.D.

ABSTRACT
Background Patients with chronic forms of major
depression are difficult to treat, and the relative efficacy of medications and psychotherapy is uncertain.
Methods We randomly assigned 681 adults with a
chronic nonpsychotic major depressive disorder to
12 weeks of outpatient treatment with nefazodone
(maximal dose, 600 mg per day), the cognitive behavioral-analysis system of psychotherapy (16 to 20
sessions), or both. At base line, all patients had
scores of at least 20 on the 24-item Hamilton Rating
Scale for Depression (indicating clinically significant
depression). Remission was defined as a score of 8 or
less at weeks 10 and 12. For patients who did not
have remission, a satisfactory response was defined
as a reduction in the score by at least 50 percent
from base line and a score of 15 or less. Raters were
unaware of the patients’ treatment assignments.
Results Of the 681 patients, 662 attended at least
one treatment session and were included in the analysis of response. The overall rate of response (both remission and satisfactory response) was 48 percent in
both the nefazodone group and the psychotherapy
group, as compared with 73 percent in the combinedtreatment group (P<0.001 for both comparisons).
Among the 519 subjects who completed the study, the
rates of response were 55 percent in the nefazodone
group and 52 percent in the psychotherapy group, as
compared with 85 percent in the combined-treatment
group (P<0.001 for both comparisons). The rates of
withdrawal were similar in the three groups. Adverse
events in the nefazodone group were consistent with
the known side effects of the drug (e.g., headache,
somnolence, dry mouth, nausea, and dizziness).
Conclusions Although about half of patients with
chronic forms of major depression have a response
to short-term treatment with either nefazodone or a
cognitive behavioral-analysis system of psychotherapy, the combination of the two is significantly more
efficacious than either treatment alone. (N Engl J Med
2000;342:1462-70.)
©2000, Massachusetts Medical Society.
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RADITIONALLY thought of as an episodic, remitting illness, major depressive disorder often has a chronic course, with protracted episodes or incomplete remission
between episodes.1-3 At any given time, at least 3 percent of the U.S. population suffers from chronic depression.4,5 Chronic forms of major depression are
associated with more marked impairments in psychosocial function and work performance,6-8 increased
health care utilization,5,9 and more frequent suicide
attempts and hospitalization10 than acute depression.
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Because they frequently begin early in life11 and are
often lifelong, chronic forms of major depression account for an inordinate proportion of the enormous
burden of illness associated with depression.12
Several studies have demonstrated the efficacy of
antidepressants as both initial13-16 and maintenance17,18
treatment for chronic forms of major depression, but
controlled clinical trials of sufficient size to examine
the efficacy of psychotherapy in chronic forms of
major depression are lacking.19 The combination of
pharmacotherapy and psychotherapy has been recommended as the treatment of choice for depression
by practice guidelines for psychiatrists 20 and as the
treatment of choice for chronic forms of major depression in primary care practice.21 However, the results of studies investigating whether combination
treatment is superior to single treatments have been
inconclusive.22-24
We present the main findings from the initial (12week) phase of a long-term multicenter study comparing nefazodone alone, the cognitive behavioralanalysis system of psychotherapy alone,25,26 or the two
in combination with regard to efficacy in the treatment of patients with chronic forms of major depression. Nefazodone has had demonstrated efficacy
in placebo-controlled trials and in numerous double-blind trials of short-term treatment of major depressive disorders,27 as well as a demonstrated ability
to prevent relapse after such treatment.28
The cognitive behavioral-analysis system of psychotherapy was developed specifically for the treatment of chronic forms of major depression and produced promising results in a small, open trial.29 This
approach draws on many behavioral, cognitive, and
interpersonal techniques used in other forms of psychotherapy.30-32 It teaches patients to focus on the
consequences of their behavior and to use a social
problem-solving algorithm to address interpersonal
difficulties. It is more structured and directive than
interpersonal psychotherapy30 and differs from cognitive therapy31 by focusing primarily on interpersonal interactions (including those with therapists). In
this type of psychotherapy, patients learn how their
cognitive and behavioral patterns produce and perpetuate their interpersonal problems and learn how
to remedy maladaptive patterns of interpersonal behavior.
METHODS
Patients
We studied outpatients, recruited from 12 academic centers between June 1996 and December 1997, who fulfilled the criteria
for a chronic major depressive disorder (at least two years’ duration), a current major depressive disorder superimposed on a preexisting dysthymic disorder, or a recurrent major depressive disorder with incomplete remission between episodes in a patient
with a current major depressive disorder and a total duration of
continuous illness of at least two years. Diagnoses were based on
the Diagnostic and Statistical Manual of Mental Disorders, fourth

edition (DSM-IV),33 and were obtained with use of the Structured Clinical Interview for Axis I DSM-IV Disorders.34
To be eligible for the study, the patients had to be between the
ages of 18 and 75 years and to have had a score of at least 20 on
the 24-item Hamilton Rating Scale for Depression (HRSD)35 at
screening and, after a two-week drug-free period, at base line. On
this scale, higher scores indicate more severe depression. Laboratory tests, electrocardiography (if clinically indicated), and physical examinations were performed at the time of screening. Patients were required to discontinue taking monoamine oxidase
inhibitors and fluoxetine at least four weeks before study entry,
depot neuroleptic agents at least six months before entry, and
other psychotropic medications at least two weeks before entry.
Patients were excluded from the study if they had any of the
following: a history of seizures, abnormal findings on electroencephalography, severe head trauma, or stroke; evidence suggesting they were at high risk for suicide; a history of psychotic symptoms or schizophrenia; bipolar disorder, an eating disorder (if it
had not been in remission for at least one year), obsessive–compulsive disorder, or dementia; antisocial, schizotypal, or severe
borderline personality disorder; a principal diagnosis of panic, generalized anxiety, social phobia, or post-traumatic stress disorders or
any substance-related abuse or dependence disorder (except those
involving nicotine) within six months before the study began; absence of a response to a previous adequate trial of nefazodone or
a cognitive behavioral-analysis system of psychotherapy; absence
of a response to three previous adequate trials of at least two different classes of antidepressants or electroconvulsive therapy or to
two previous adequate trials of empirical psychotherapy in the
three years preceding the study; a serious, unstable medical condition; or a positive urine screen for drugs of abuse. Women of
childbearing potential had to agree to use adequate contraception
during the study. Patients were not allowed to take anxiolytic
agents, sedatives, hypnotic agents, or any other types of sleep aids
(pharmacologic or behavioral) during the study.
Study Design
The institutional review board at each center approved the study.
All patients provided written informed consent. Patients who remained eligible at the end of the two-week evaluation period were
randomly assigned, according to a central computerized randomization schedule, in a 1:1:1 ratio to receive nefazodone (Serzone,
Bristol-Myers Squibb), psychotherapy, or a combination of nefazodone and psychotherapy. The Structured Clinical Interview for
Axis I DSM-IV Disorders and the HRSD were administered by
experienced clinical raters (study coordinators) certified to have a
high rate of interrater reliability and level of procedural integrity.
Each site implemented procedures to mask the patient’s treatment
assignment from the person who evaluated the results of the
HRSD, and the degree of adherence to these procedures was
monitored at each study visit. At all sites the rater was located at
a separate physical location so that he or she could not see patients arriving for or departing from treatment sessions.
Among the patients who received nefazodone, the initial dose
was 200 mg per day (100 mg twice a day) and was increased to
300 mg per day during the second week. Thereafter, the dose was
increased weekly in increments of 100 mg per day to a maximum
of 600 mg per day, to maximize the efficacy of the drug without
producing intolerable side effects. To remain in the study, patients
had to be receiving a dose of at least 300 mg per day by week 3.
Visits for medication were limited to 15 to 20 minutes. Psychopharmacologists followed a published manual36 for clinical management (e.g., patients were questioned about the concomitant
use of medications and symptoms, side effects, and illnesses they
had had between visits). The psychopharmacologists were not allowed to make formal psychotherapeutic interventions (such as
suggesting ways to cope with stressful life events).
The cognitive behavioral-analysis system of psychotherapy also
followed a manual37 specifying twice-weekly sessions during weeks
1 through 4 and weekly sessions during weeks 5 through 12. Twice-
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weekly sessions could be extended until week 8 if a patient was
not adequately performing a learned social problem-solving procedure according to the criteria.
Psychotherapists (persons who had at least two years’ experience after earning an M.D. or Ph.D. or at least five years’ experience after earning an M.S.W.) attended a two-day training workshop and met the criteria for mastery of treatment procedures
involved in the cognitive behavioral-analysis system of psychotherapy, as assessed by evaluation of their performance during
two videotaped pilot cases. All psychotherapy sessions conducted
during the study were videotaped, and supervisors reviewed the
videotapes weekly to assess the psychotherapists’ adherence to the
treatment procedures.
Outcome Measures
The score on the 24-item HRSD was the primary outcome.
The Global Assessment of Functioning Scale (Axis V in the DSMIV) was administered at base line, and the results were evaluated
by the same person who evaluated the HRSD results. Remission
was defined a priori as an HRSD score of no more than 8 at both
week 10 and week 12 for those who completed the 12-week protocol and at the time of withdrawal for those who did not complete the study. A satisfactory therapeutic response was defined as
a reduction in the HRSD score by at least 50 percent from base
line to week 10 and week 12, with a total score of 15 or less at
these times but of more than 8 at week 10, week 12, or both for
those who completed the study and at the time of departure for
those who did not complete the study. The patients with these
favorable outcomes were combined to form a single response group.
All other patients were considered to have had no response.
Statistical Analysis
The base-line demographic and clinical characteristics of the
treatment groups were compared with the use of analysis of variance for continuous variables and the Cochran–Mantel–Haenszel
test for categorical variables, with site as the stratification variable.
Preliminary paired t-tests were conducted separately for each treatment group to examine the significance of the changes in the
HRSD scores from base line to the end point.
No outcome data were collected on patients who withdrew from
the study after they withdrew, and a formal intention-to-treat analysis thus could not be performed. The primary analysis was a modified intention-to-treat analysis that included all patients who attended at least one treatment visit and who had at least one
assessment after the base-line evaluation. Patients who underwent
randomization but who did not return for a subsequent assessment were therefore not included in this analysis. Given this modified approach, the main efficacy analysis was a piecewise mixedeffects linear model that examined the relative differences between
treatments with respect to the rate of change in the HRSD score
(the linear slope) from base line to week 4 as one variable and
from week 4 to week 12 (or the last visit) as a second variable.
The a priori rationale for examining the first four weeks separately
was that the earliest antidepressant effects of nefazodone are likely
to occur at week 4 if a stable dosage has been achieved. Each
model estimated fixed effects with respect to treatment and site,
as well as the interactions between treatment and time. In addition, the models included a random intercept and a random slope.
Interactions between treatment and site were not significant and
therefore were not included in the models. The statistical significance of additional terms included in successive models was determined by the likelihood-ratio test. The error structure was specified as nonstationary autocorrelation in each model. There were
no interim analyses of the data.
In addition to the mixed-model analysis, we examined response
and remission rates that were based on the total HRSD score. We
used the Cochran–Mantel–Haenszel test to analyze these rates in
the modified intention-to-treat sample and among the patients
who completed the study (with site as the stratification variable).
We also performed an analysis of covariance of the change in total
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TABLE 1. STATUS OF THE 681 PATIENTS DURING THE 12-WEEK
STUDY, ACCORDING TO THE TREATMENT ASSIGNMENT.

STATUS

NEFAZODONE PSYCHOTHERAPY
(N=226)
(N=228)

NEFAZODONE AND
PSYCHOTHERAPY
(N=227)

number (percent)

Included in modified inten- 220 (97)
tion-to-treat sample*
Completed the study
167 (74)
Withdrew from the study
59 (26)
Lack of efficacy
2 (1)
Adverse events
31 (14)
Withdrew consent
11 (5)
Protocol violation
2 (1)
Lost to follow-up
7 (3)
Other reasons
6 (3)

216 (95)

226 (>99)

173
55
3
3
32
2
0
15

179
48
3
16
17
0
1
11

(76)
(24)
(1)
(1)
(14)
(1)
(7)

(79)
(21)
(1)
(7)
(7)
(<1)
(5)

*The modified intention-to-treat sample consisted of all randomized patients who attended at least one treatment visit and who had at least one
efficacy assessment after the base-line evaluation.

HRSD scores from base line to the end point, with base-line
scores as the covariate, on these two samples. The model included
treatment and site as the main effects. The interactions between
treatment and site were again not significant and, hence, were not
included in the model. We made pairwise comparisons of the
means of the three treatment groups (adjusted for base-line values) using simple contrasts. Overall differences between treatments
were evaluated with use of an alpha level of 0.05, whereas pairwise comparisons used an alpha level of 0.0167 (0.05÷3) with
Bonferroni’s correction.
We used Fisher’s exact test to analyze the incidence of adverse
events and rate of discontinuation of treatment in the three
groups. All statistical tests were two-tailed. The data analysis was
done by a biostatistical data-management company (Statprobe,
Ann Arbor, Mich.), according to a plan devised by the authors.
The company was selected and paid by Bristol-Myers Squibb.

RESULTS
Base-Line Clinical and Demographic Characteristics

A total of 1035 patients were screened for the
study. Of the 354 who did not undergo randomization, 235 (66 percent) did not meet the study criteria, 47 (13 percent) withdrew their consent, and 72
(20 percent) were excluded for other reasons (e.g.,
failure to return for further evaluation or noncompliance). A total of 681 patients underwent randomization: 226 were assigned to receive nefazodone, 228
to receive psychotherapy, and 227 to receive combined treatment (Table 1). Randomization was not
stratified according to site. At each site, approximately equal numbers of patients underwent randomization to the three groups. However, there were no significant differences among the groups with respect to
base-line demographic and clinical characteristics (Table 2), either among the sites overall or within sites.
Treatment

For the modified intention-to-treat sample, the
mean (±SD) final daily dose of nefazodone was 466±
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TABLE 2. BASE-LINE CHARACTERISTICS

CHARACTERISTIC

Female sex (%)
Age (yr)
White race (%)
Marital status (%)
Married or cohabiting
Single
Widowed
Divorced or separated
Depression diagnosis (%)
Chronic major depression
MDD with dysthymic disorder
Recurrent depression, with incomplete remission
between episodes
Age at onset of MDD (yr)
Age at onset of dysthymia (yr)
Duration of current episode of MDD (yr)
Duration of current episode of dysthymia (yr)
History of anxiety disorder (%)
Diagnosis of coexisting personality disorder (%)
History of alcohol- or substance-abuse disorder (%)
Prior treatment with antidepressants (%)
Prior psychotherapy (%)
Prior treatment with both antidepressants and
psychotherapy (%)
No prior treatment for depression (%)
Global Assessment of Functioning score†

OF THE

PATIENTS.*

NEFAZODONE
(N=226)

PSYCHOTHERAPY
(N=228)

NEFAZODONE AND
PSYCHOTHERAPY
(N=227)

64.2
42.2±11.0
87.2

62.7
43.2±10.8
91.7

69.2
44.4±10.3
92.5

42.9
27.4
2.7
27.0

41.6
30.3
1.3
26.8

43.6
23.8
2.2
30.4

42.7
27.2
2.1
28.0

36.7
42.9
20.4

35.5
39.9
24.6

33.0
44.1
22.9

35.1
42.3
22.6

ALL PATIENTS
(N=681)

65.3
43±10.7
90.5

25.6±13
17.8±13
7.5±9
22.3±15
33.6
59.3
34.5
57.5
65.9
43.4

27.5±13
19.7±14
7.8±10
22.5±15
28.5
53.9
33.3
59.5
61.2
42.3

27.1±13
20.3±14
8.0±9.5
24.2±16
36.1
63.0
31.7
63.6
68.4
49.6

26.7±13
19.3±14
7.8±9.6
23.0±15
32.7
58.7
33.2
60.2
65.2
45.1

19.9
53.8±5.4

22.0
53.9±5.7

17.1
53.6±5.6

19.7
54.0±5.6

*Plus–minus values are means ±SD. MDD denotes major depressive disorder.
†The score on the Global Assessment of Functioning Scale, which assesses the overall severity of psychiatric symptoms
and functional impairment, can range from 1 to 100. Scores ranging from 1 to 20 indicate a patient who is a danger to
others or to himself or herself. Scores ranging from 21 to 40 indicate a patient with moderate-to-severe impairments who
should be hospitalized. Scores ranging from 41 to 60 indicate a patient with serious, nonpsychotic symptoms that impair
function. Scores ranging from 61 to 80 indicate a patient with mild or transient symptoms who may require occasional
counseling and psychotherapy. Scores ranging from 81 to 100 indicate a person with good functioning who does not
require counseling.

144 mg in the nefazodone group (data available for
216 patients) and 460±139 mg in the combinedtreatment group (221 patients). Among the patients
who completed the study and for whom data on dose
were available, the mean final daily dose of nefazodone was 520±100 mg among 92 patients with a
response in the nefazodone group and 479±111 mg
among the 152 patients with a response in the combined-treatment group. The dose was 491±125 mg
among 73 patients without a response in the nefazodone group and 539±96 mg among the 27 patients
without a response in the combined-treatment group.
For the modified intention-to-treat sample, the average number of psychotherapy sessions was 16.0±4.7
among 216 patients in the psychotherapy group and
16.2±4.8 among 226 patients in the combinedtreatment group. Among those who completed the
study, the 90 patients with a response in the psychotherapy group and the 152 such patients in the combined-treatment group attended a mean of 18.2±1.9

sessions, whereas the number was 17.7±1.9 among
the 83 patients in the psychotherapy group who had
no response and 17.9±1.4 among the 27 patients in
the combined-treatment group who had no response.
Efficacy

Analyses revealed a significant improvement within patients in the HRSD scores from base line to
week 12 in the group of patients who completed the
study (P<0.001) and from base line to the last follow-up visit in the modified intention-to-treat sample (P<0.001) in all three groups. The mixed-effects
piecewise linear regression examining the course of
the scores during the 12 weeks of the trial (Fig. 1)
showed that from base line through week 4, the average rate of improvement in the scores for patients
in the combined-treatment group was not significantly different from the average rate of improvement in
the scores for patients in the nefazodone group (P=
0.39). However, the results of the analysis of the rate
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Nefazodone andG 226 210 212 206 201
psychotherapy

181G
174G
197

164G
168G
184

160G
166G
182

153G
156G
173

Figure 1. Mean Scores on the Hamilton Rating Scale for Depression during the 12-Week Study.
The results of the analysis of the rate of improvement in the scores as a regression slope were as follows: for base line through week 4, P<0.001 for the comparison of combined treatment and psychotherapy, P=0.004 for the comparison of nefazodone and psychotherapy, and P=0.39 for the comparison of combined treatment and nefazodone; and for weeks 4 through 12, P<0.001 for the comparison
of combined treatment and nefazodone and of psychotherapy and nefazodone and P=0.06 for the
comparison of combined treatment and psychotherapy.

TABLE 3. RATES

GROUP

OF

RESPONSE

NEFAZODONE PSYCHOTHERAPY

AND

REMISSION.*

NEFAZODONE AND
PSYCHOTHERAPY

P VALUE
NEFAZODONE VS.

PSYCHOTHERAPY VS.

NEFAZODONE VS.

COMBINED

COMBINED

PSYCHOTHERAPY

TREATMENT

TREATMENT

no. of patients (%)

Modified intention-to-treat sample
No. of patients
Response
Remission
Satisfactory response
No response
Patients who completed the study
No. of patients
Response
Remission
Satisfactory response
No response

220
105
64
41
113

(48)
(29)
(19)
(51)

216
103
72
31
113

(48)
(33)
(14)
(52)

226
165
109
56
57

(73)
(48)
(25)
(25)

0.92
0.37
0.21

<0.001
<0.001
0.10

<0.001
<0.001
0.004

167
92
36
56
73

(55)
(22)
(34)
(44)

173
90
41
49
83

(52)
(24)
(28)
(48)

179
152
75
77
27

(85)
(42)
(43)
(15)

0.57
0.64
0.30

<0.001
<0.001
0.07

<0.001
<0.001
0.004

*The responses of two patients in the nefazodone group who completed the study could not be determined because no scores were available
for the Hamilton Rating Scale for Depression at week 10 or 12. In the modified intention-to-treat sample, no post-randomization scores were
available for two patients in the nefazodone group and four in the combined-treatment group. Remission was defined as a score of no more
than 8 at both week 10 and week 12 for those who completed the 12-week protocol and when they left the trial for those who did not
complete the study. A satisfactory response was defined as a reduction in the score by at least 50 percent from base line to week 10 and week
12, with a total score of 15 or less at these times but of more than 8 at week 10, week 12, or both for those who completed the study and
at the time of departure for those who did not complete the study.
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of improvement in the scores as a regression slope
showed significant differences between the nefazodone
group and the psychotherapy group (P=0.004) and
between the combined-treatment group and the psychotherapy group (P<0.001). From week 4 through
week 12, the average rate of improvement in the
HRSD scores for patients in the combined-treatment
group was significantly larger than the rate of improvement in scores for patients in the nefazodone
group (P<0.001). There was also a significant difference in the rate of improvement in scores between
the psychotherapy group and the nefazodone group
(P<0.001) but not between the combined-treatment
group and the psychotherapy group (P=0.06).
The overall rate of response was significantly higher in the combined-treatment group than in the nefazodone group or the psychotherapy group in both
the modified intention-to-treat sample and the group
of patients who completed the study (P<0.001 for
all comparisons) (Table 3). For the modified intention-to-treat sample, the overall rates of response were
48 percent in the psychotherapy group (95 percent
confidence interval, 41.5 to 54.8 percent), 48 percent in the nefazodone group (95 percent confidence
interval, 41.0 to 54.3 percent), and 73 percent in the
combined-treatment group (95 percent confidence
interval, 68.6 to 80.1 percent) at the time of the last
follow-up visit. Among the patients who completed
the 12 weeks of treatment, the overall rates of response were 52 percent in the psychotherapy group
(95 percent confidence interval, 44.6 to 59.6 percent), 55 percent in the nefazodone group (95 percent confidence interval, 47.5 to 62.6 percent), and
85 percent in the combined-treatment group (95

percent confidence interval, 79.7 to 90.2 percent).
In both samples of patients, significantly more patients had a remission during combined treatment
than during treatment with nefazodone or psychotherapy alone (P<0.001 for all comparisons) (Table
3). In the modified intention-to-treat sample, the remission rates were 33 percent in the psychotherapy
group, 29 percent in the nefazodone group, and 48
percent in the combined-treatment group. The respective rates of remission among the patients who
completed the study were 24 percent, 22 percent,
and 42 percent.
An analysis of covariance revealed significant differences between treatment groups with respect to the
final HRSD scores for both the modified intention-totreat sample (Table 4) and in the patients who completed the study, with combined treatment more effective than either psychotherapy alone or nefazodone
alone (P<0.001 for all comparisons). To examine the
size of the differences between combined treatment
and treatment with nefazodone or psychotherapy
alone, we calculated effect sizes using Cohen’s d (the
difference between adjusted means divided by the
pooled standard deviation). The effect sizes calculated for the group of patients who completed the study
and for the modified intention-to-treat sample ranged
from 0.54 to 0.64 for the comparison of combined
treatment with the other two groups. There were no
significant differences at end point between the nefazodone group and the psychotherapy group.
Rates of Discontinuation and Adverse Events

The rates of discontinuation were similar in the
three groups (P=0.46) (Table 1), with 24 percent of

TABLE 4. MEAN SCORES ON THE HAMILTON RATING SCALE FOR DEPRESSION
AT BASE LINE, WEEK 12, AND THE LAST FOLLOW-UP VISIT.*

VARIABLE

Score
Nefazodone
Psychotherapy
Nefazodone and psychotherapy
P value for comparison between groups
Nefazodone vs. psychotherapy
Nefazodone vs. combined treatment
Psychotherapy vs. combined treatment
Effect sizes (Cohen’s d) for pairwise
comparisons‡
Nefazodone vs. psychotherapy
Nefazodone vs. combined treatment
Psychotherapy vs. combined treatment

NO. OF
PATIENTS

BASE LINE

WEEK 12

LAST FOLLOW-UP
VISIT

220
216
226

26.8±0.32
26.4±0.33
27.4±0.32

14.7±0.70†
15.1±0.69†
9.7±0.65†

15.8±0.64†
16.0±0.63†
10.8±0.63†

0.68
<0.001
<0.001

0.79
<0.001
<0.001

¡0.05
0.59
0.64

¡0.02
0.54
0.56

*Plus–minus values are means ±SE. Higher scores on the 24-item test indicate more severe depression. Values for week 12 represent data from patients who completed the study, whereas values
for the last follow-up visit represent data from the modified intention-to-treat sample.
†P<0.001 for the comparison with base-line score by the paired t-test.
‡The effect sizes were calculated as the difference between the adjusted means divided by the
pooled standard deviation.
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all patients not completing the 12-week study. The
percentage of patients who dropped out because of
lack of efficacy was low (1 percent in each group).
The rate of discontinuation due to adverse events
was 14 percent in the nefazodone group, 7 percent
in the combined-treatment group, and 1 percent in
the psychotherapy group. The most common reason
for discontinuing psychotherapy was withdrawal of
consent (in 14 percent of patients). Of the 32 patients who withdrew their consent, 5 did not want
psychotherapy, 11 thought treatment was too time
consuming, and 4 wanted medication. Seventy-two
percent of the patients in the psychotherapy group
who withdrew their consent did so within the first
four weeks of treatment.
Table 5 lists the adverse events (whether or not
they were thought to be related to treatment) that
occurred in at least 10 percent of all patients. The adverse events in the groups receiving nefazodone were
consistent with the known side effects of the medication, with headache, somnolence, dry mouth, nausea, and dizziness being the most common. Weight
gain was rare, with no instances in the nefazodone
or psychotherapy group and an incidence of 3.1 per-

TABLE 5. COMMON ADVERSE EVENTS.*

PSYCHONEFAZODONE
(N=225)

ADVERSE EVENT

NEFAZODONE
PSYCHO-

AND

THERAPY

THERAPY

(N=221)

(N=226)

P
VALUE†

65
20
21
18
12
12
35
36
19
23
17
36
29
19
14
8
10
10
10
20
10

<0.001
<0.001
0.02
0.08
0.50
0.23
<0.001
<0.001
0.02
<0.001
<0.001
<0.001
<0.001
0.004
<0.001
<0.001
<0.001
0.05
0.89
<0.001
<0.001

percent

Headache
Asthenia
Pain
Abdominal pain
Infection
Back pain
Dry mouth
Nausea
Dyspepsia
Diarrhea
Constipation
Somnolence
Dizziness
Insomnia
Lightheadedness
Agitation
Difficulty concentrating
Pharyngitis
Sinusitis
Abnormal vision
Blurred vision

56
17
14
13
9
8
39
30
21
19
16
40
25
19
12
10
9
12
12
15
11

45
6
12
10
13
10
0
6
12
10
1
1
2
8
<1
2
1
5
11
<1
1

*Adverse events that were reported by at least 10 percent of all patients
are listed.
†Fisher’s exact test was used to test for differences among the three
groups.
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cent in the combined-treatment group. Sexual dysfunction (including impotence, psychosexual dysfunction, anorgasmia, and abnormal ejaculation) occurred
in 3.5 percent of the patients in the nefazodone group,
none of the patients in the psychotherapy group,
and 3.5 percent of the patients in the combinedtreatment group.
DISCUSSION

We found that treatment with a combination of
nefazodone and psychotherapy had significant advantages over treatment with nefazodone or psychotherapy alone. Despite the fact that the patients had
had active depression for many years and that many
had other psychiatric disorders as well, among the
patients who completed the study, 85 percent of the
patients in the combined-treatment group had a response to treatment by week 12, as compared with
55 percent of patients in the nefazodone group and
52 percent of patients in the psychotherapy group.
The rates of response and remission in the combined-treatment group were substantially higher than
those that might have been anticipated on the basis
of the outcomes of previous trials in similar patients.
By contrast, in the modified intention-to-treat sample, the rate of response of 48 percent in both the
nefazodone group and the psychotherapy group was
similar to the rates reported for treatment with sertraline (52 percent),13 imipramine (51 percent),13 and
desipramine (51 percent)18 in other studies of patients with chronic depression. The degree of superiority of combination therapy over monotherapy, as
indicated by differences in the response rates and the
sizes of the effects, suggests that combined treatment
provides a clinically meaningful advantage. These results support previous recommendations,21 based on
clinical experience, for the use of both psychotherapy and medication to treat patients with chronic depression.
Nefazodone produced effects more rapidly than did
psychotherapy, with significant advantages evident in
the first four weeks, whereas psychotherapy had a
greater effect during the second part of the trial. By
week 12, the efficacy of the two approaches was similar. Although patients who were receiving nefazodone
had higher frequencies of adverse events than those
receiving psychotherapy, the rates of withdrawal from
the study were similar in all three treatment groups.
The fact that the efficacy of combined treatment and
nefazodone was similar during the first four weeks of
the study but that combined treatment was more efficacious later in the study suggests that when medication and psychotherapy are administered together,
they continue to have independent rather than synergistic mechanisms of action.
A limitation of our study was the lack of a placebo
control. However, a placebo-controlled study of patients with either a chronic major depressive disorder
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alone or a major depressive disorder plus dysthymia
reported a relatively low rate of response to placebo
(12 percent).14 In a study on the treatment of chronic forms of depression, the use of a placebo control
would most likely greatly decrease the number of patients willing to participate, thereby reducing the generalizability of the findings.38
Another limitation, common to all studies of psychotherapy, was our inability to mask patients and
therapists in the psychotherapy groups. To counteract this limitation, we had persons who were unaware
of the patients’ treatment assignments administer the
HRSD. However, the clinicians were obviously not
unaware of the treatment that patients were receiving.
Further limitations of our study include the restrictive exclusion criteria, which also reduced the generalizability of the findings, and the rates of withdrawal
in conjunction with the lack of further data on patients after they withdrew. The slightly lower rate of
withdrawal in the combined-treatment group (21
percent) than in the nefazodone group (26 percent)
or the psychotherapy group (24 percent) may have
biased the outcome comparisons.
In summary, we found that the combination of
pharmacotherapy (nefazodone) and the cognitive behavioral-analysis system of psychotherapy was significantly more efficacious than either treatment alone
for outpatients with chronic forms of depression. The
rates of response to either treatment alone were similar and were also similar to the rates reported in previous trials of antidepressants for the treatment of
chronic forms of depression in outpatients, indicating that at least one form of psychotherapy is effective in treating such patients. Although similarly effective, nefazodone produced effects more rapidly than
did psychotherapy.
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